((自动化翻译由路透提供，请见免责声明 ))
11月11日 - ** 制药商艾伯维 股价盘前下跌12%至175.93美元
** 该公司称其精神分裂症实验药物依普拉啶（emraclidine）未能达到两项中期试验的主要目标
** ABBV去年以87亿美元收购了Cerevel Therapeutics公司，从而获得了这种药物。
** 竞争对手百时美施贵宝 的股价盘前上涨13%至61.13美元
** BMY的药物Cobenfy（又称KarXT）是一种治疗精神分裂症的新型药物，已于9月份获得美国FDA批准。
** 精神分裂症是一种导致持续妄想和幻觉的疾病，严重影响患者对现实的感知能力
** 截至上次收盘，ABBV 累计上涨约 29%，BMY 累计上涨 5.5
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.